Home > Oncology > ASCO 2020 > Melanoma > Adjuvant pembrolizumab: durable RFS for stage III melanoma

Adjuvant pembrolizumab: durable RFS for stage III melanoma

Presented By
Prof. Alexander Eggermont, Princess Máxima Centre, NL
ASCO 2020
Phase 3, EORTC 1325-MG/KEYNOTE-054
Featured video: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up. https://vimeo.com/440624363   At 3-years median follow-up, the randomised, phase 3 EORTC 1325/KEYNOTE-054 trial demonstrated that adjuvant pembrolizumab taken for up to 1 year in high-risk stage III melanoma patients improved recurrence-free survival (RFS), with a consistent effect across subgroups. Prof. Alexander Eggermont (Princess Máxima Centre for Paediatric Oncology, the Netherlands) presented the study [1], whose purpose was to assess whether post-surgery therapy with pembrolizumab improves disease recurrence for high-risk participants with melanom...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on